News Conference News VIVA 2024 DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years L.A. McKeown November 11, 2024
News Conference News VIVA 2024 Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK L.A. McKeown November 05, 2024
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2021 Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI L.A. McKeown October 08, 2021
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News VIVA 2017 EVAR Outcomes Equivalent Between Men and Women, Registries Show L.A. McKeown September 14, 2017